Decoding C‑SH2 Domain/Peptide Interactions in SH2 Domain-Containing Tyrosine Phosphatase 2: A Molecular Framework for...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• SHP2 (PTPN11) is crucial for cell processes and a cancer target.
• Mutations cause developmental and hematological disorders.
• SHP2 inhibition is a promising cancer therapy strategy.

Purpose of the Study:

• To explore targeting the C-SH2 domain of SHP2 for protein-protein interaction inhibition.
• To identify features governing C-SH2 binding affinity and specificity for inhibitor design.
• To develop novel peptide inhibitors for wild-type and mutant SHP2.

Main Methods:

• Molecular dynamics (MD) simulations of C-SH2/peptide complexes.
• Analysis of peptide libraries, ligand sequences, and experimental structures.
• Identification of key residues for C-SH2 binding and selectivity.

Main Results:

• Defined features for C-SH2 binding affinity and specificity.
• Identified optimal residue types at positions +1 to +5 for C-SH2 interaction.
• MD simulations revealed transient N-terminal interactions not seen in crystal structures.

Conclusions:

• The C-SH2 domain is a viable target for SHP2 inhibition.
• Specific residue characteristics enhance C-SH2 binding and selectivity.
• Findings enable the design of novel peptide inhibitors targeting SHP2 C-SH2 domain.